ORLANDO—A rare inherited form of skin cancer — basal cell nevus syndrome — has been controlled by an inhibitor of the “hedgehog” molecular pathway in a study reported to the American Assoc
Ervin Epstein
ORLANDO—A rare inherited form of skin cancer — basal cell nevus syndrome — has been controlled by an inhibitor of the “hedgehog” molecular pathway in a study reported to the American Association for Cancer Research annual meeting held in Orlando. Ervin Epstein, Senior Scientist at the Children’s Hospital of the Oakland Research Institute in California, presented the first drug study in man to harness the anti-hedgehog pathway for treating cancer. He talks with ecancer radio about the importance of his group’s findings.
LISTEN
[audio:https://www.audiomedica.com/podcasting/ecancer/110405ErvinEpsteinPODCASTLoRes.mp3]
Related Episodes
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths
An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Ce
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere
An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington, CT And with: Jayesh Desai MD, Medical Oncologist,
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer
An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institut